Silo Pharma Competitors and Similar CompaniesClear all

Silo Pharma's competitors and similar companies include Indivior, Autifony Therapeutics, PolyNeuroS and Ethismos Research.

	Silo Pharma Silo Pharma is a developmental stage biopharmaceutical company focusing on merging traditional therapeutics with psychedelic research for people suffering from neurological disorders.	Indivior Indivior is a pharmaceutical company focused on developing treatments for substance use disorders and mental health conditions.	Autifony Therapeutics Autifony Therapeutics is a biotechnology company that develops new drugs to treat serious disorders of the central nervous system.	PolyNeuroS PolyNeuroS is a biotech company developing small molecule antibodies.	Ethismos Research Ethismos Research is a drug discovery company developing therapies to address addiction and depression.
Founding Date	Founding Date 2010	Founding Date 2014	Founding Date 2011	Founding Date N/A	Founding Date N/A
Type	Type Public	Type Subsidiary	Type Private	Type Private	Type Private
Tags	Tags Healthcare distribution drug development mental health pharma therapy	Tags Healthcare drug development mental health pharma	Tags Healthcare biotech drug development mental health pharma therapy	Tags Healthcare biotech distribution drug development mental health pharma	Tags Healthcare drug development mental health pharma therapy
Locations	Locations Englewood Cliffs, US HQ	Locations Kingston upon Hull, GB HQ	Locations Stevenage, GB HQ Padova, IT	Locations Saint-Jean-d'Illac, FR HQ Villenave D'ornon, FR	Locations Cambridge, US HQ
Employees	Employees 350% increase	Employees 1,0946% decrease	Employees 3017% decrease	Employees 340% decrease	Employees 18
Financial
Revenue (est.)	Revenue (est.) $72.1k (FY, 2025)	Revenue (est.) $1.2b (FY, 2025)	Revenue (est.) £22.8m (FY, 2018)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods $44.3k (FY, 2025)	Cost of goods $233m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $27.8k (FY, 2025)	Gross profit $1b (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income ($4.2m) (FY, 2025)	Net income $210m (FY, 2025)	Net income £16.2m (FY, 2018)	Net income N/A	Net income N/A